Shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) have earned an average rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $29.33.
A number of analysts recently weighed in on COLL shares. ValuEngine downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, February 12th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald set a $35.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Friday, February 8th. BidaskClub downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 9th. Finally, HC Wainwright started coverage on Collegium Pharmaceutical in a research note on Friday, May 3rd. They issued a “buy” rating and a $23.00 price target on the stock.
Shares of Collegium Pharmaceutical stock traded down $0.33 during trading on Monday, reaching $12.80. The company’s stock had a trading volume of 2,614 shares, compared to its average volume of 422,195. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.19. Collegium Pharmaceutical has a 12-month low of $12.39 and a 12-month high of $28.91. The company has a market cap of $436.24 million, a PE ratio of -10.76 and a beta of 0.25.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $15.09, for a total transaction of $377,250.00. Following the sale, the director now directly owns 207,170 shares in the company, valued at $3,126,195.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 75,000 shares of company stock worth $1,176,750. 8.08% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. MERIAN GLOBAL INVESTORS UK Ltd purchased a new stake in Collegium Pharmaceutical during the first quarter worth $26,000. First Quadrant L P CA purchased a new stake in Collegium Pharmaceutical during the first quarter worth $36,000. Meeder Asset Management Inc. boosted its position in Collegium Pharmaceutical by 644.8% during the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after purchasing an additional 3,179 shares in the last quarter. Great West Life Assurance Co. Can boosted its position in Collegium Pharmaceutical by 206.1% during the first quarter. Great West Life Assurance Co. Can now owns 4,286 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 2,886 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new stake in Collegium Pharmaceutical during the fourth quarter worth $103,000.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
See Also: Balance Sheet
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.